Jonathan has a degree in chemistry and a doctorate in synthetic chemistry from Oxford University, UK. He is a Fellow of the Royal Society of Chemistry and a Chartered Scientist. Jonathan is a member of the Board of HGF Limited and is the head of the Asia Team at HGF.
Jonathan's practice involves providing commercially-focussed advice on patent origination, patent strategy and portfolio management, licensing and due diligence, prosecuting and defending European patent oppositions, and conducting patent litigation in the UK and Europe.
His practice draws in this variety of experience and extends to a wide range of chemical and pharmaceutical subject matter. Jonathan's practice in the pharmaceutical area has covered both contentious and non-contentious issues and he has provided external consultancy services to a number of large pharmaceutical companies over the last 20 years.
His practice involves providing commercially focused advice to C-suite business leaders, R&D groups, and public institutions on all aspects of patent strategy and portfolio management. This includes obtaining and defending patent rights, providing opinions on freedom to operate where third party intellectual property rights exist, conducting due diligence to support corporate acquisition and licensing deals, challenging third party patent rights and pan-European pharmaceutical litigation.
Jonathan has worked on a number of high profile pharmaceutical matters including working as part of the patent drafting/procurement team for Viagra™; prosecution and litigation surrounding Augmentin™, Ritalin™ and Fosrenol™; opposition/appeal work on Zithromax™, and due diligence work to support the acquisitions of New River Pharmaceuticals (Vyvanse™) and Renovo.
In the non-pharmaceutical area, he has also been responsible for filing all of the foundation patents for graphene on behalf of Manchester University's Nobel Prize winners Geim and Novoselov.
Jonathan's clients include large and small companies, universities and government funded organisations.